NRXS NeurAxis Inc. Gross Return on Sales

NRXS (NeurAxis, Inc) - company brandmark

NeurAxis, Inc. (NRXS) is implementing eco-friendly production standards while protecting its market share with an FDA-approved neurostimulation method. The gross profit margin reflects profitability dynamics, where the 86.20 mark characterizes this parameter. The company has achieved a breakthrough in non-invasive therapy by creating a wearable device to alleviate pediatric abdominal pain without the use of medication.

NeurAxis (NRXS): Return on Gross Profit from 02/21/2024 to 11/20/2026

Analytical breakdowns and data insights for company NeurAxis, Inc. (NRXS)

- current quotes and average value forecast:
Summary company analysis:NeurAxis Inc.
Brand item of NeurAxis Inc

Demand for NeurAxis, Inc. (NRXS) neurostimulation systems remains stable due to the critical necessity of pain therapy, establishing a foundation for high operational efficiency. The gross margin history reflects the profit share after deducting direct production costs, allowing investors to assess the business's ability to convert revenue into capital and maintain sustainable market value within the defensive medtech sector.

Main competitors

Return on Gross Profit Biogen Corp|Return on Gross Profit NBIX|Regencell Corp (RGC) - Return on Sales by Gross Profit|Gross Margin AXSM|Return on Gross Profit ACADIA Pharmaceuticals ACAD|Gross Margin XENE (Xenon Pharmaceuticals Inc.)|VKTX (Viking Therapeutics, Inc.) - Gross Profitability Margin|SUPN - Gross Profitability|Catalyst Pharmaceuticals Inc (CPRX) - Return on Gross Profit|DNLI (Denali Corp) - Return on Gross Profit|Gross Profit Margin harmonybiosciences.com (HRMY)|Return on Gross Profit BHVN|Gross Margin Amylyx|Gross Margin TRVI|PRAX (Praxis Corp) - Gross Profit Rate|Gross Margin AVXL (anavex.com)|CBLL: Gross Return on Sales|PRTA - Gross Profitability|ALEC - Gross Margin|Annexon Inc. (ANNX) - Gross Profitability|Return on Gross Profit Omeros Corp|Return on Gross Profit NGNE|ACIU: Gross Profit Rate|Return on Gross Profit VYGR (Voyager Corp)|Return on Gross Profit Neumora NMRA|Gross Profitability Scilex Holding Company, Inc. SCLX|Gross Sales Margin Tevogen Bio Inc.|ACOG - Gross Profitability|Gross Sales Margin Cognition Therapeutics (CGTX)|IKT (Inhibikase Therapeutics) - Return on Gross Profit|Cassava Sciences Inc (SAVA) - Gross Margin|Return on Gross Profit ASRT|Gross Margin coyatherapeutics.com|Gross Margin VTGN|Ovid Therapeutics - Gross Return on Sales|Gross Margin ABOS (Acumen Pharmaceuticals, Inc)|CRVO - Return on Gross Profit|ATHE - Gross Profitability|Return on Sales by Gross Profit clene.com CLNN|PEPG: Gross Margin|Gross Return on Sales JUNS|RLMD (Relmada Corp) - Gross Margin|Annovis Bio Inc (ANVS) - Return on Sales by Gross Profit|Gross Profitability Grace Therapeutics, Inc. (GRCE)|AIFF (Firefly Neuro) - Gross Profit Rate|Gross Profitability Klotho Neurosciences KLTO|NRSN: Gross Return on Sales|RVPH: Return on Gross Profit|MTVA: Gross Profitability|HSDT: Gross Margin|PASG - Return on Sales by Gross Profit|Gross Profitability Neuphoria Therapeutics, Inc.|Gross Profitability NERV|Gross Margin ATHA|ADXN (Addex Therapeutics Ltd) - Gross Profit Rate|Gross Profitability alzamend.com ALZN|Return on Sales by Gross Profit Cyclerion Therapeutics (CYCN)|Protagenic - Gross Margin|Gross Profit Rate KTTA (Pasithea Therapeutics Corp)|CRGT: Gross Margin|Avenue Therapeutics Inc. (ATXI) - Gross Margin|BCLI (BrainStorm Cell Therapeutics Inc.) - Gross Margin|Gross Margin Cara Therapeutics Inc|Gross Profitability Chromocell Therapeutics (CHRO)|Gross Profit Ratio ELYM|Gross Profitability Intra-Cellular ITCI|LBPH: Gross Return on Sales|MRNS - Gross Profitability|NKGen Biotech, Inc. (NKGN) - Return on Gross Profit|neurobopharma.com (NRBO) - Gross Profitability|SAGE: Gross Profit Ratio|Gross Profitability Synaptogenix, Inc.|Gross Profitability TRVN|Gross Margin VIGL|Gross Margin anewmeds.com (WENA)|Gross Margin CERE (cerevel.com)